#Sweden #Epigenica #EpiFinder #GenomePro #Solna

Introduction

Epigenica AB, a trailblazer in epigenomic innovation, has officially launched its revolutionary product, the EpiFinder™ GenomePro. Utilizing groundbreaking technology, this product is set to redefine the landscape of epigenomic research by allowing scientists to investigate the complex interplay of histone post-translational modifications (hPTMs) and DNA methylation at an unprecedented scale.

What is EpiFinder™ GenomePro?

EpiFinder™ GenomePro is the next generation of the EpiFinder™ platform, designed to optimize epigenomic studies. This state-of-the-art tool facilitates the analysis of 24 samples in a single run, yielding robust and quantitative data on 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles simultaneously. Researchers can now achieve these exceptional results from minimal sample volumes, which significantly reduces the cost per sample and makes large-scale studies more feasible than ever before.

Key Features

One of the standout features of EpiFinder™ GenomePro is its flexibility. Researchers can customize the selection of hPTMs, with or without accompanying DNA methylation data, thus tailoring their experiments to their specific research needs.

Additionally, the product includes an open-source data analysis pipeline. This commitment to transparency ensures that researchers can easily reproduce their findings, fostering collaborative efforts across the scientific community. Mohamad Takwa, CEO of Epigenica AB, articulated the vision behind this innovation: "With EpiFinder™ GenomePro, we're setting a new standard in epigenomic research. Our goal is to enable researchers to tackle complex biological questions with unprecedented depth and scale."

Implications for Research

The introduction of EpiFinder™ GenomePro is poised to significantly advance research across various therapeutic areas. By decoding the epigenetic mechanisms that drive disease onset and progression, the platform has the potential to enhance predictions of patient treatment responses. This high-resolution data can help scientists uncover novel biomarkers and map intricate disease processes, leading to the development of targeted precision therapies.

Björn Reinius, Associate Professor at the Karolinska Institute, emphasized the accessibility of the EpiFinder™ GenomePro, stating, "The EpiFinder GenomePro kit offers an excellent method for labs with limited previous experience in ChIP-seq to obtain high-quality data without significant time investment." This inclusivity opens the doors for many laboratories to engage in high-level research.

A Vision for the Future

Epigenica AB is focused on empowering researchers through the tools necessary for generating multiplex, high-throughput, and quantifiable data in a more cost-effective manner. As a life sciences technology company founded in Stockholm, Sweden in 2020, Epigenica is dedicated to innovations in epigenetic research. The EpiFinder platform exemplifies this commitment, offering comprehensive epigenetic studies at unmatched speed and affordability.

By providing a diverse array of products based on the EpiFinder platform, the company increases accessibility to high-throughput profiling methods at varying scales and depths. This advancement is instrumental in driving progress in biomedical research, drug discovery, precision medicine, diagnostics, and therapeutic strategies for conditions associated with aging.

Conclusion

The unveiling of EpiFinder™ GenomePro marks a significant milestone in the realm of epigenomic research. By enabling deeper insights into epigenetic regulation, it stands to unlock a wealth of knowledge that can influence future therapeutic strategies. For those interested in exploring how EpiFinder™ GenomePro can elevate their research, additional details can be found on the official Epigenica AB website at www.epigenica.se.

About Epigenica

Epigenica is committed to providing superior solutions for research in epigenetics, offering researchers the ability to conduct advanced studies that not only enhance scientific knowledge but also contribute to improved healthcare outcomes worldwide.